RedHill Biopharma Announced The Placement Of Low-dose Rifabutin-triple Therapy, Talicia, As An Empirically-prescribed First-line Option For Helicobacter Pylori Infection In The Newly Published American College Of Gastroenterology Clinical Guideline

BenzingaSep 9 07:14 ET

RedHill Biopharma Announces ADS Ratio Change

TipRanksSep 5 08:57 ET

RedHill Biopharma Regains Compliance With Nasdaq

Seeking AlphaSep 5 07:18 ET

Redhill Biopharma Announced The Publication Of Data, In Journal Microorganisms, From The Phase 2/3 Study Of Opaganib In Covid-19 Pneumonia That Showed 62% Reduction In Covid-19 Mortality

BenzingaSep 3 07:14 ET

Express News | Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY

BenzingaAug 29 07:07 ET

RedHill Biopharma Cash Balance of $8.2 M as of June 30 >RDHL

Dow JonesAug 29 07:03 ET